dm+d

Unassigned

New Medicines

Information

New molecular entity
Pfizer
Pfizer

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Inhibitor of p38 mitogen-activated protein (MAP) kinase. Dosed at 400mg twice daily.
It is difficult to know the true prevalence but it is estimated at around 1 in 2,500. Genetic inheritance arises in 35% of patients. Mutations in 60 genes have been associated with dilated cardiomyopathy [1]. Lamin A/C gene is among the most common cardiomyopathy-causing gene. Cardiomyopathies induced by these mutations have a very aggressive and fast clinical course that could culminate with sudden cardiac death from malignant ventricular arrhythmias and end-stage heart failure [2].
Dilated cardiomyopathy due to lamin A/C gene mutations (LMNA-related DCM) - first-line in adults
Oral